Roche announced that the European Commission (EC) has given its approval for the wider use of Avastin (bevacizumab) in patients suffering from metastatic colorectal cancer. The new broader label will now allow Avastin to be used in combination with any chemotherapy, including Roche's oral chemotherapy Xeloda (capecitabine), for first and later treatment lines in patients with metastatic colorectal cancer.